Core Viewpoint - Edwards Lifesciences Corporation is facing a class action lawsuit due to allegations of misleading investors regarding the growth prospects of its Transcatheter Aortic Valve Replacement (TAVR) platform [1][3]. Group 1: Company Disclosures and Performance - Throughout the class period, Edwards Lifesciences assured investors of "strong sustainable growth" for the TAVR platform, projecting healthy double-digit growth and the potential for acceleration in 2025 and beyond [2]. - The company later revealed that TAVR sales grew only 5% and reduced its growth guidance from 8-10% to 5-7% [4]. - The decline in TAVR growth was attributed to increased competition from structural heart therapies, which impacted hospital workflows [4]. Group 2: Investor Reactions and Market Impact - Following the disappointing Q2 2024 results, analysts downgraded Edwards Lifesciences shares and lowered their price targets, questioning the company's explanations regarding physician capacity versus demand [4]. - The share price dropped by $27.25, a decrease of 31%, resulting in a loss of over $16 billion in shareholder value in a single day [4]. Group 3: Legal and Investigative Actions - Hagens Berman is investigating whether Edwards Lifesciences misled investors about the TAVR business and growth prospects amid increasing competition [5]. - The firm encourages investors who suffered losses to submit their claims and provides information for whistleblowers with non-public information [5].

Have you evaluated the performance of Edwards Lifesciences' (EW) international operations during the quarter that concluded in September 2024? Considering the extensive worldwide presence of this medical device maker, analyzing the patterns in international revenues is crucial for understanding its financial resilience and potential for growth.The global economy today is deeply interlinked, making a company's engagement with international markets a critical factor in determining its financial success and gr ...

SAN DIEGO, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Edwards Lifesciences Corporation (NYSE: EW) securities between February 6, 2024 and July 24, 2024, inclusive (the "Class Period"), have until December 13, 2024 to seek appointment as lead plaintiff of the Edwards Lifesciences class action lawsuit. Captioned Patel v. Edwards Lifesciences Corporation, No. 24-cv-02221 (C.D. Cal.), the Edwards Lifesciences class action lawsuit charges Edwards ...

NEW YORK, Oct. 27, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Edwards Lifesciences Corporation (NYSE: EW) between February 6, 2024 and July 24, 2024, both dates inclusive (the "Class Period"), of the important December 13, 2024 lead plaintiff deadline. SO WHAT: If you purchased Edwards securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arr ...

I discussed my "Strong Buy" thesis on Edwards Lifesciences Corporation (NYSE: EW ) in July 2024 and bought the dip after the company cut its guidance in Q2 FY24 . Since then, the stock price has surged by Analyst's Disclosure: I/we have a beneficial long position in the shares of EW either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationshi ...

Core Insights - Edwards Lifesciences Corporation is facing a class action lawsuit due to alleged misleading statements and failure to disclose material adverse facts regarding its business and operations during the Class Period from February 6, 2024, to July 24, 2024 [1][3] Financial Performance - On July 24, 2024, Edwards Lifesciences reported fiscal second quarter 2024 results that fell below expectations and lowered projections for its core Transcatheter Aortic Valve Replacement (TAVR) platform for the full fiscal year 2024 [2] - Following the announcement, the stock price of Edwards Lifesciences dropped by $27.25, or 31.34%, closing at $59.70 per share on July 25, 2024 [2] Allegations in the Lawsuit - The class action complaint alleges that the Company did not have reliable information regarding projected revenue and growth, and that its growth was at risk of deceleration [3] - It is claimed that the Company's "patient activation activities" did not effectively target the low-treatment-rate population necessary for TAVR's growth, and that the Company overstated hospital interest in TAVR procedures compared to newer structural heart therapies [3] - The lawsuit asserts that the positive statements made by the Company about its business and prospects were materially misleading and lacked a reasonable basis [3]

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Edwards To Contact Him Directly To Discuss Their OptionsIf you suffered losses exceeding $100,000 in Edwards between February 6, 2024 and July 24, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).[You may also click here for additional information]NEW YORK, Oct. 25, 2024 /PRNewswire ...

Edwards Lifesciences Corporation (EW) reported third-quarter 2024 adjusted earnings per share (EPS) of 67 cents, in line with the Zacks Consensus Estimate. The figure increased 21.8% from the year-ago quarter's level. On this note, GAAP EPS from continuing operations was 61 cents compared with 55 cents in the third quarter of 2023. The quarter's one-time adjustments primarily include certain litigation expenses and amortization of intangible assets. In the quarter, the company completed the sale of Critical ...

Financial Data and Key Metrics Changes - The company reported third quarter sales from continuing operations of $1.35 billion, reflecting a 9.6% underlying sales growth [20][21] - Adjusted earnings per share for the quarter was $0.67, slightly ahead of expectations [20] - The adjusted gross profit margin was elevated at 80.7%, slightly higher year-over-year and sequentially [22][23] - The company expects fourth quarter gross margin to align with the high end of its full year guidance range of 76% to 78% [22][62] Business Line Data and Key Metrics Changes - TAVR global sales reached $1 billion in the third quarter, increasing 6% when adjusted for currency [8][12] - TMTT sales were $91 million, representing a 74% growth over the prior year, driven by PASCAL growth globally [14] - Surgical sales from continuing operations were $240 million, increasing 5% over the prior year [16] Market Data and Key Metrics Changes - In the U.S., TAVR sales growth was in line with global growth, with hospitals exploring investments to address future workflow needs [10][12] - In Europe, the market position improved sequentially, supported by the launch of SAPIEN 3 Ultra RESILIA [11] - Japan experienced slower market growth, impacting results, but the company remains focused on addressing under-treatment of AS [11] Company Strategy and Development Direction - The company aims to position TAVR for long-term growth through differentiated technologies and global initiatives [6][7] - New therapeutic areas such as aortic regurgitation and implantable heart failure management are being explored [7][18] - The company is committed to expanding its portfolio and driving sustainable growth through innovative therapies [7][27] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term growth opportunities driven by innovative therapies and strong clinical evidence [27] - The company anticipates challenges in the fourth quarter due to one-time items and fewer selling days compared to the third quarter [26] - Management remains optimistic about the ability of hospitals to scale and support trans-catheter procedure growth over time [10][46] Other Important Information - The company closed the sale of critical care in September, which impacted financial results [21] - The company repurchased $1 billion of stock during the third quarter, with approximately $1.4 billion remaining under its share repurchase authorization [25] - The company expects to provide detailed 2025 financial guidance at an investor conference in December [26] Q&A Session Summary Question: Clarification on Q4 guidance and EPS - Management indicated that the elimination of critical care impacted earnings per share by about $0.35, along with additional expenses from acquisitions [30][32] Question: Impact of hurricanes and China on Q4 guidance - Management clarified that the China adjustment was a one-time rebate and that there are three fewer selling days in Q4 compared to Q3 [35][36] Question: Competitive dynamics and market share - Management acknowledged the competitive landscape but emphasized the strength of their clinical evidence and technology, maintaining a premium pricing strategy [71][72] Question: Updates on EVOQUE and NCD - Management is optimistic about the NCD process for EVOQUE and expects a draft by year-end, with full support for CMS efforts [50][51]

Edwards Lifesciences (EW) reported $1.35 billion in revenue for the quarter ended September 2024, representing a year-over-year decline of 8.5%. EPS of $0.67 for the same period compares to $0.59 a year ago. ...